Sorrento Therapeutics (LTS:0L85) EPS (Basic): $-1.12 (TTM As of Jun. 2023)


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics EPS (Basic)?

Sorrento Therapeutics LTS:0L85 12 EPS (Basic) is $-1.12 as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

Sorrento Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2023 was $-0.17. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.12.

Sorrento Therapeutics's EPS (Diluted) for the three months ended in Jun. 2023 was $-0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.12.

Sorrento Therapeutics's EPS without NRI for the three months ended in Jun. 2023 was $-0.14. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -0.77.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Sorrento Therapeutics  (LTS:0L85) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sorrento Therapeutics EPS (Basic) Related Terms

Sorrento Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics EPS (Basic) Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.92 -2.20 -1.30 -1.45 -1.37

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 -0.20 -0.49 -0.26 -0.17
LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sorrento Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-572.843-0)/419.315
=-1.37

Sorrento Therapeutics's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-95.212-0)/551.281
=-0.17

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.12 mean?
Sorrento Therapeutics (LTS:0L85) has a EPS (Basic) of $-1.12 as of Jun. 2023. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sorrento Therapeutics and its competitors.
Is Sorrento Therapeutics' EPS (Basic) too high?
Sorrento Therapeutics' current EPS (Basic) is $-1.12. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' EPS (Basic) compare to IMUX and OCUP?
Sorrento Therapeutics' EPS (Basic) of $-1.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sorrento Therapeutics and its competitors. Sorrento Therapeutics's current EPS (Basic) is $-1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (LTS:0L85) has a current EPS (Basic) of $-1.12. The current EPS (Basic) is $-1.12. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current EPS (Basic) is $-1.12 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price